United States Drug Patent 12,569,543: Scope, Claim Structure, and Patent Landscape
US Drug Patent 12,569,543 is a method-of-use patent that covers preventing major adverse cardiovascular events (MACE) in subjects with type 2 diabetes and cardiovascular disease using semaglutide administered once weekly by subcutaneous injection at a defined dose range and optionally with additional limiting criteria (CV disease subtypes, BMI, duration of dosing, and a defined injectable formulation composition and pH).
What exactly is claimed?
The claims define a therapeutic method (not a composition product) and narrow the covered activity by:
- Indication: type 2 diabetes plus cardiovascular disease
- Clinical endpoint: MACE consisting of CV death, non-fatal MI, non-fatal stroke
- Drug: semaglutide
- Administration route and schedule: subcutaneous injection once weekly
- Dose range: 0.05 to 2.0 mg once weekly
- Additional optional limitations (dependent claims): CV disease evidence category, prior events and risk markers; BMI limit; minimum treatment duration; and a specific injectable formulation with quantified excipients and pH.
1) What is the independent claim scope?
Claim 1 (broadest independent position)
Claim 1 covers:
- A method of reducing risk of MACE in a subject
- Population: subject has type 2 diabetes and cardiovascular disease
- Treatment: administering a pharmaceutical composition comprising semaglutide
- Dose and schedule: 0.05-2.0 mg once weekly by subcutaneous injection
- MACE definition: CV death, non-fatal MI, and non-fatal stroke
Claim 8 (second independent, narrower CV evidence set)
Claim 8 is substantively similar, with one meaningful shift:
- It also covers reducing MACE with semaglutide 0.05-2.0 mg once weekly SC in type 2 diabetes with cardiovascular disease.
- It defines the CV disease differently and provides a more limited list than Claim 2’s full evidence taxonomy.
Net effect: Claim 1 and Claim 8 give two independent “anchors” with overlapping but not identical boundary conditions around what counts as cardiovascular disease.
2) How do the dependent claims narrow the covered class?
Claim 2 and Claim 8’s CV disease limitation
Claim 2 is a highly specific CV disease evidence split that expands definitional coverage while creating hard edges on what qualifies.
Clinical evidence of cardiovascular disease (Claim 2)
Includes:
- prior myocardial infarction
- prior stroke or transient ischemic attack
- prior coronary, carotid, or peripheral arterial revascularization
- >50% stenosis on angiography or imaging (coronary, carotid, or lower extremity)
- history of symptomatic coronary heart disease
- asymptomatic cardiac ischemia
- heart failure
- chronic renal impairment by eGFR <60 mL/min/1.73 m² per MDRD
Subclinical evidence of cardiovascular disease (Claim 2)
Includes:
- persistent microalbuminuria or proteinuria
- hypertension and left ventricular hypertrophy by ECG or imaging
- left ventricular systolic or diastolic dysfunction
- ankle/brachial index <0.9
Claim 8 includes a shorter list (Claim 2’s Clinical evidence subset plus some items), including:
- prior MI
- prior stroke or TIA
- prior coronary/carotid/peripheral revascularization
-
50% stenosis on imaging
- symptomatic coronary heart disease history
- asymptomatic cardiac ischemia
- heart failure
- chronic renal impairment (eGFR <60 MDRD)
Claim 3 and Claim 9 (BMI cap)
This adds a subject-eligibility restriction that could matter for carve-outs in payer protocols, trial inclusion criteria, or real-world prescribing segments.
Claim 4 and Claim 10 (duration)
- semaglutide administered for at least 30 months.
This creates a temporal requirement that can be outcome-sensitive: shorter exposure regimens may fall outside claim scope depending on enforcement theory and timing of MACE assessment.
Claims 5-7 and 11-13 (formulation and pH constraints)
These claims introduce a second axis of narrowing: the injected semaglutide product must have specific excipient concentrations and pH.
General formulation envelope (independent narrowing claims)
Claims 5 and 11 require the pharmaceutical composition with:
- semaglutide: 0.1-20 mg/mL
- phosphate buffer: 2-15 mM
- propylene glycol: 2-25 mg/mL
- phenol: 1-18 mg/mL
- pH: 7.0-9.0
Specific exemplary formulation (precision narrowing)
Claims 6 and 12 require, at the concentration and pH level:
- semaglutide: 1.34 mg/mL
- disodium phosphate dihydrate: 1.42 mg/mL
- propylene glycol: 14.0 mg/mL
- phenol: 5.5 mg/mL
- pH: 7.4
Claims 7 and 13 repeat essentially the same specific formulation language.
Note on claim architecture: dependent claims make the scope conjunctive. In infringement analysis, an accused method would need to satisfy all limitations of the asserted dependent claim, not just the semaglutide and clinical endpoint elements.
3) What is the practical “coverage map” of the claims?
Coverage dimensions
The claims layer restrictions across four dimensions:
-
Indication + population
- type 2 diabetes
- cardiovascular disease defined by clinical and/or subclinical evidence
-
Endpoint
- MACE = CV death, non-fatal MI, non-fatal stroke
-
Treatment parameters
- semaglutide
- 0.05-2.0 mg once weekly
- subcutaneous injection
-
Optional add-ons (dependent claims)
- CV disease evidence category (clinical vs subclinical evidence taxonomy)
- BMI ≤ 30 kg/m²
- duration ≥ 30 months
- specific formulation excipient concentrations and pH (either range or specific point formulation)
Claim boundary summary table
| Claim |
Anchor method |
Dose/schedule/route |
CV disease definition |
Additional narrowing |
| 1 |
Reduce MACE risk |
0.05-2.0 mg once weekly SC |
Type 2 diabetes + CV disease (broad in claim text; detailed evidence in dependent claim 2) |
None in Claim 1 |
| 2 |
Same as Claim 1 |
Same |
CV disease split: clinical evidence + subclinical evidence with hard item lists |
BMI not included here; duration not included here |
| 3 |
Same as Claim 1 |
Same |
As per Claim 1 (and whatever is satisfied by Claim 2 if asserted with 2) |
BMI ≤ 30 kg/m² |
| 4 |
Same as Claim 1 |
Same |
As per Claim 1 |
Treatment duration ≥ 30 months |
| 5 |
Same as Claim 1 |
Same |
As per Claim 1 |
Formulation ranges (semaglutide/excipients/pH) |
| 6 |
Same as Claim 1 |
Same |
As per Claim 1 |
Specific formulation: 1.34 mg/mL semaglutide; specific excipients; pH 7.4 |
| 7 |
Same as Claim 1 |
Same |
As per Claim 1 |
Repeats specific formulation language |
| 8 |
Reduce MACE risk |
0.05-2.0 mg once weekly SC |
CV disease defined with a specific list (mostly “clinical evidence” items) |
None in Claim 8 |
| 9 |
Same as Claim 8 |
Same |
As per Claim 8 |
BMI ≤ 30 kg/m² |
| 10 |
Same as Claim 8 |
Same |
As per Claim 8 |
Duration ≥ 30 months |
| 11 |
Same as Claim 8 |
Same |
As per Claim 8 |
Formulation ranges |
| 12 |
Same as Claim 8 |
Same |
As per Claim 8 |
Specific formulation |
| 13 |
Same as Claim 8 |
Same |
As per Claim 8 |
Repeats specific formulation |
4) What is the implied infringement trigger logic?
A method accused of infringement would generally need to align on:
- Semaglutide used for MACE risk reduction
- Population match: type 2 diabetes and cardiovascular disease under the claim’s definition
- Treatment match: once-weekly subcutaneous dosing in the 0.05-2.0 mg window
- Endpoint match: MACE includes CV death, non-fatal MI, non-fatal stroke
- If asserted as a dependent claim: also satisfy the BMI threshold, dosing duration, and/or formulation specs.
This yields three common enforcement postures:
- Independent-claim posture (Claim 1 or 8): broadest boundary; formulation and duration not required.
- Dependent posture on subject stratification: BMI and CV evidence taxonomy.
- Dependent posture on product/formulation: pH and excipient concentration constraints.
5) How does this shape the broader US semaglutide patent landscape?
What kind of protection this is
US 12,569,543 is a method-of-use protection that overlays an established GLP-1 RA active ingredient (semaglutide) with a specific clinical use scenario and dosing parameters.
Landscape effect for competitors and lifecycle strategists
Even when a competitor can legally market a semaglutide product, the patent landscape can still block or pressure:
- labeling and commercialization language (MACE risk reduction in defined populations)
- payer clinical pathways that mirror claim patient eligibility and endpoints
- off-label or structured protocols that include the dose window and the endpoint definition
Practical freedom-to-operate pressure points created by the claims
These are the highest-friction elements for a design-around strategy:
- Dose range: 0.05-2.0 mg once weekly SC. A product or protocol using semaglutide outside the range may avoid a literal reading of the method claims, but then raises legal risk in equivalents.
- Endpoint definition: the MACE grouping is explicit and standard in cardiovascular outcomes trials. Protocols claiming broader endpoints may still be argued to “select from” the listed MACE events.
- CV disease definition: Claim 2’s clinical and subclinical evidence list is detailed. Protocols that restrict only to narrower definitions may aim to avoid claim coverage, but the list includes common risk markers (e.g., heart failure, asymptomatic ischemia criteria, AAI threshold).
- Duration: ≥30 months is a temporal gate.
- Formulation specifics: requiring excipient concentration and pH can be a stronger product-level hook for method claims that incorporate formulation constraints. Many competitors replicate formulations under regulatory constraints, so this may reduce carve-out opportunities.
6) What does the claim set suggest about prosecution and claim strategy?
The claim set uses a layered strategy:
- Two independent claims (1 and 8) cover MACE risk reduction in type 2 diabetes with cardiovascular disease, but Claim 2 expands CV disease evidence types (including subclinical evidence).
- The formulation claims include both broad ranges (0.1-20 mg/mL, phosphate 2-15 mM, propylene glycol 2-25 mg/mL, phenol 1-18 mg/mL, pH 7.0-9.0) and a specific formulation point (1.34 mg/mL semaglutide, disodium phosphate dihydrate 1.42 mg/mL, propylene glycol 14.0 mg/mL, phenol 5.5 mg/mL, pH 7.4).
- Duplication across Claim 6 vs Claim 7 and Claim 12 vs Claim 13 suggests tight drafting to maintain coverage continuity even if typographical or transcriptional issues arise in the formulation recitations.
Key Takeaways
- US 12,569,543 is a semaglutide method-of-use patent focused on reducing MACE risk in type 2 diabetes with cardiovascular disease using once-weekly subcutaneous semaglutide 0.05-2.0 mg.
- Independent coverage (Claims 1 and 8) centers on the treatment method and MACE definition; dependent claims add hard gates for CV evidence taxonomy, BMI ≤ 30, duration ≥ 30 months, and formulation excipient/pH specs.
- The practical highest-friction elements for design-around are the dose window, the MACE event list, and (if asserted) the formulation pH and excipient concentration constraints.
- Claim 2 materially expands eligibility by adding a subclinical cardiovascular evidence branch (e.g., microalbuminuria/proteinuria, LVH, ankle/brachial index <0.9).
FAQs
1) Does the patent protect a semaglutide product itself or only a method?
It protects a method of reducing MACE risk, not a standalone semaglutide composition claim (based on the provided claim set).
2) What is the semaglutide dosing range covered?
0.05 to 2.0 mg once weekly by subcutaneous injection.
3) What events define MACE under these claims?
Cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
4) When do formulation requirements matter?
Only if the asserted claim is a dependent claim with formulation limitations (Claims 5-7 and 11-13).
5) Is “cardiovascular disease” limited to clinical events?
No. Claim 2 explicitly includes both clinical and subclinical evidence of cardiovascular disease.
References
[1] Provided claim text for US Drug Patent 12,569,543 (Claims 1-13).
